Innate Pharma (IPHA) Competitors $2.17 +0.06 (+2.84%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA vs. TNGX, MNMD, MAZE, NAGE, UPB, DAWN, KALV, AMLX, AVBP, and GYREShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Tango Therapeutics (TNGX), Mind Medicine (MindMed) (MNMD), Maze Therapeutics (MAZE), Niagen Bioscience (NAGE), Upstream Bio (UPB), Day One Biopharmaceuticals (DAWN), KalVista Pharmaceuticals (KALV), Amylyx Pharmaceuticals (AMLX), ArriVent BioPharma (AVBP), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Its Competitors Tango Therapeutics Mind Medicine (MindMed) Maze Therapeutics Niagen Bioscience Upstream Bio Day One Biopharmaceuticals KalVista Pharmaceuticals Amylyx Pharmaceuticals ArriVent BioPharma Gyre Therapeutics Innate Pharma (NASDAQ:IPHA) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Does the media favor IPHA or TNGX? In the previous week, Innate Pharma and Innate Pharma both had 1 articles in the media. Tango Therapeutics' average media sentiment score of 0.50 beat Innate Pharma's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in IPHA or TNGX? 0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 7.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is IPHA or TNGX more profitable? Innate Pharma has a net margin of 0.00% compared to Tango Therapeutics' net margin of -322.67%. Innate Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Tango Therapeutics -322.67%-62.75%-39.94% Which has more risk and volatility, IPHA or TNGX? Innate Pharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Do analysts recommend IPHA or TNGX? Innate Pharma currently has a consensus target price of $11.00, suggesting a potential upside of 411.63%. Tango Therapeutics has a consensus target price of $10.50, suggesting a potential upside of 60.80%. Given Innate Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Innate Pharma is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, IPHA or TNGX? Innate Pharma has higher earnings, but lower revenue than Tango Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$21.77M9.10-$53.53MN/AN/ATango Therapeutics$40.99M17.27-$130.30M-$1.22-5.35 SummaryInnate Pharma beats Tango Therapeutics on 8 of the 14 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.51M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E RatioN/A17.6228.6723.80Price / Sales9.10179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book19.558.508.275.55Net Income-$53.53M-$55.06M$3.24B$259.03M7 Day Performance5.39%-3.98%-3.69%-4.59%1 Month Performance18.13%9.59%4.33%4.46%1 Year Performance0.23%6.72%25.95%18.03% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma2.352 of 5 stars$2.15+1.9%$11.00+411.6%-1.4%$194.51M$21.77M0.00220Gap UpTNGXTango Therapeutics1.6674 of 5 stars$6.67-2.2%$10.50+57.4%-30.9%$739.25M$42.07M-5.4790Upcoming EarningsGap DownMNMDMind Medicine (MindMed)1.9042 of 5 stars$9.68-0.8%$24.00+147.9%+0.7%$737.40MN/A-7.5040News CoverageEarnings ReportAnalyst ForecastMAZEMaze TherapeuticsN/A$16.36-2.7%$25.60+56.5%N/A$736.67M$167.50M0.00121Lockup ExpirationNAGENiagen Bioscience1.0385 of 5 stars$9.69+4.0%$13.22+36.4%N/A$734.13M$99.60M57.00120Analyst DowngradeUPBUpstream Bio2.0252 of 5 stars$14.34+5.2%$56.50+294.0%N/A$733.21M$2.37M0.0038Upcoming EarningsGap DownHigh Trading VolumeDAWNDay One Biopharmaceuticals2.2584 of 5 stars$7.10-1.8%$29.00+308.5%-53.1%$732.85M$131.16M-10.0060Upcoming EarningsKALVKalVista Pharmaceuticals3.8567 of 5 stars$13.57-6.9%$26.29+93.7%-4.5%$728.33MN/A-3.68100AMLXAmylyx Pharmaceuticals2.5111 of 5 stars$7.99-2.0%$11.75+47.1%+272.9%$726.50M$87.37M-2.57200Upcoming EarningsAVBPArriVent BioPharma2.0202 of 5 stars$20.93-1.2%$39.29+87.7%-13.2%$724.62MN/A-5.5540Positive NewsGYREGyre TherapeuticsN/A$7.81+2.2%N/A-52.4%$716.31M$105.76M390.7040 Related Companies and Tools Related Companies TNGX Alternatives MNMD Alternatives MAZE Alternatives NAGE Alternatives UPB Alternatives DAWN Alternatives KALV Alternatives AMLX Alternatives AVBP Alternatives GYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPHA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
